Side effects - Heart - Chronic Myeloid Leukemia - CML
The potential for QT prolongation associated with nilotinib and dasatinib, although rare, necessitates vigilant monitoring.
ARTICLES
Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
October 22, 2020, docwirenews
Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19
Mar 29, 2020, American College of Cardiology
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitor
October 24, 2019, PubMed
Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management
October 7, 2019, Acta Haematologica
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice
May 1, 2019, PubMed
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs
March 26, 2019, PubMed
The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
June 12, 2018, NCBI
Cardiovascular Health Considerations When Using Tyrosine Kinase Inhibitors
May 4, 2018, JNCCN360
1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML
April 9, 2018, Oncology Nurse Advisor
Peripheral Artery Occlusive Disease Among Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Case-Control Study
December 15, 2017, PublMed
The effect of aspirin and anticoagulation on tyrosine kinase inhibitors induced thrombotic events in chronic myeloid leukemia: A retrospective cohort
May 30, 2017, Journal of Clinical Oncology
Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)
December 3, 2016, ASH 2016
BCR-ABL Tyrosine Kinase Inhibitors May Increase Cardiovascular Events in Chronic Myeloid Leukemia
February 16, 2016, Cancer Therapy Advisor
CML arterial adverse events rate dependent on TKI choice
October 22, 2015, News Medical
Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
March 5, 2015, BJC
Life-saving cancer drug can also cause heart damage: Study
February 14, 2014, Ottawa Citizen
Ageing is a risk factor in imatinib mesylate cardiotoxicity
February 6, 2014, PublMed
Nilotinib-Associated Vascular Events.
May 23, 2012, PublMed
Clinical cardiac safety profile of nilotinib.
January 22, 2012, PubLMed
FDA Drug Safety Communication: Sprycel (dasatinib) and risk of pulmonary arterial hypertension
November 10, 2011, U.S. Food and Drug Administration
A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib
August 2010, Leukemia Research
Reversible Cardiotoxicity with tyrosine kinase inhibitors
February 2010, Clinical advances In Hematology & Oncology
Effect of nilotinib on the pharmacokinetics and pharmacodynamics of warfarin
2009 ASCO annual meeting
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
July 2009, Journal Blood
Leukemia Drug May Improve Stroke Treatment
June 2008, WebMed
Cancer Drug Gleevec Could Fight Stroke
June 2008, HealthDay - eVitamine
Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
October 22, 2020, docwirenews
Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19
Mar 29, 2020, American College of Cardiology
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitor
October 24, 2019, PubMed
Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management
October 7, 2019, Acta Haematologica
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice
May 1, 2019, PubMed
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs
March 26, 2019, PubMed
The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
June 12, 2018, NCBI
Cardiovascular Health Considerations When Using Tyrosine Kinase Inhibitors
May 4, 2018, JNCCN360
1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML
April 9, 2018, Oncology Nurse Advisor
Peripheral Artery Occlusive Disease Among Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Case-Control Study
December 15, 2017, PublMed
The effect of aspirin and anticoagulation on tyrosine kinase inhibitors induced thrombotic events in chronic myeloid leukemia: A retrospective cohort
May 30, 2017, Journal of Clinical Oncology
Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)
December 3, 2016, ASH 2016
BCR-ABL Tyrosine Kinase Inhibitors May Increase Cardiovascular Events in Chronic Myeloid Leukemia
February 16, 2016, Cancer Therapy Advisor
CML arterial adverse events rate dependent on TKI choice
October 22, 2015, News Medical
Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
March 5, 2015, BJC
Life-saving cancer drug can also cause heart damage: Study
February 14, 2014, Ottawa Citizen
Ageing is a risk factor in imatinib mesylate cardiotoxicity
February 6, 2014, PublMed
Nilotinib-Associated Vascular Events.
May 23, 2012, PublMed
Clinical cardiac safety profile of nilotinib.
January 22, 2012, PubLMed
FDA Drug Safety Communication: Sprycel (dasatinib) and risk of pulmonary arterial hypertension
November 10, 2011, U.S. Food and Drug Administration
A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib
August 2010, Leukemia Research
Reversible Cardiotoxicity with tyrosine kinase inhibitors
February 2010, Clinical advances In Hematology & Oncology
Effect of nilotinib on the pharmacokinetics and pharmacodynamics of warfarin
2009 ASCO annual meeting
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
July 2009, Journal Blood
Leukemia Drug May Improve Stroke Treatment
June 2008, WebMed
Cancer Drug Gleevec Could Fight Stroke
June 2008, HealthDay - eVitamine
Learn Sarver Heart Center's Continuous Chest Compression CPR
Return to the list of side effects
Return to Managing Side Effects
